Fjarde Ap-fonden’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11M | Sell |
162,594
-6,600
| -4% | -$440K | 0.05% | 286 |
|
|
2026
Q1 | $10.6M | Buy |
169,194
+59,150
| +54% | +$4.12M | 0.06% | 273 |
|
|
2025
Q4 | $7.3M | Buy |
110,044
+17,200
| +19% | +$1.11M | 0.06% | 274 |
|
|
2025
Q3 | $6.25M | Sell |
92,844
-4,800
| -5% | -$380K | 0.05% | 290 |
|
|
2025
Q2 | $8.52M | Buy |
97,644
+43,900
| +82% | +$3.44M | 0.08% | 242 |
|
|
2025
Q1 | $3.67M | Sell |
53,744
-9,600
| -15% | -$783K | 0.04% | 358 |
|
|
2024
Q4 | $4.93M | Sell |
63,344
-2,700
| -4% | -$200K | 0.05% | 345 |
|
|
2024
Q3 | $4.43M | Buy |
+66,044
| New | +$5.42M | 0.05% | 367 |
|
|
2024
Q1 | $7.75M | Buy |
55,844
+800
| +1% | +$101K | 0.09% | 253 |
|
|
2023
Q4 | $6.83M | Buy |
55,044
+5,000
| +10% | +$511K | 0.09% | 243 |
|
|
2023
Q3 | $4.67M | Sell |
50,044
-7,100
| -12% | -$800K | 0.06% | 327 |
|
|
2023
Q2 | $7.34M | Buy |
57,144
+8,700
| +18% | +$1.05M | 0.09% | 233 |
|
|
2023
Q1 | $5.63M | Sell |
48,444
-7,500
| -13% | -$840K | 0.08% | 288 |
|
|
2022
Q4 | $6.34M | Sell |
55,944
-12,900
| -19% | -$1.42M | 0.09% | 253 |
|
|
2022
Q3 | $5.13M | Hold |
68,844
| – | – | 0.06% | 321 |
|
|
2022
Q2 | $5.13M | Sell |
68,844
-24,000
| -26% | -$2.19M | 0.06% | 321 |
|
|
2022
Q1 | $11.9M | Sell |
92,844
-8,800
| -9% | -$963K | 0.12% | 178 |
|
|
2021
Q4 | $13.6M | Sell |
101,644
-5,168
| -5% | -$743K | 0.12% | 163 |
|
|
2021
Q3 | $14.6M | Sell |
106,812
-400
| -0.4% | -$50.4K | 0.13% | 144 |
|
|
2021
Q2 | $11.4M | Sell |
107,212
-6,800
| -6% | -$653K | 0.1% | 195 |
|
|
2021
Q1 | $10.2M | Buy |
114,012
+1,600
| +1% | +$150K | 0.09% | 213 |
|
|
2020
Q4 | $10.4M | Buy |
112,412
+3,600
| +3% | +$321K | 0.1% | 200 |
|
|
2020
Q3 | $11.2M | Buy |
108,812
+3,600
| +3% | +$376K | 0.12% | 158 |
|
|
2020
Q2 | $10.7M | Sell |
105,212
-22,400
| -18% | -$2M | 0.13% | 149 |
|
|
2020
Q1 | $8.59M | Buy |
127,612
+4,400
| +4% | +$274K | 0.14% | 141 |
|
|
2019
Q4 | $6.74M | Buy |
123,212
+9,200
| +8% | +$436K | 0.08% | 254 |
|
|
2019
Q3 | $4.25M | Buy |
114,012
+7,556
| +7% | +$294K | 0.06% | 363 |
|
|
2019
Q2 | $3.99M | Sell |
106,456
-17,200
| -14% | -$541K | 0.05% | 394 |
|
|
2019
Q1 | $3.68M | Buy |
123,656
+20,456
| +20% | +$719K | 0.05% | 411 |
|
|
2018
Q4 | $3.09M | Buy |
+103,200
| New | +$3.27M | 0.05% | 362 |
|
|
2017
Q4 | – | Sell |
-95,864
| Closed | -$1.17M | – | 637 |
|
|
2017
Q3 | $1.17M | Sell |
95,864
-5,408
| -5% | -$95.6K | 0.02% | 601 |
|
|
2017
Q2 | $1.85M | Buy |
101,272
+13,504
| +15% | +$249K | 0.04% | 534 |
|
|
2017
Q1 | $1.86M | Sell |
87,768
-6,476
| -7% | -$126K | 0.04% | 498 |
|
|
2016
Q4 | $1.41M | Buy |
+94,244
| New | +$1.67M | 0.03% | 569 |
|
Other funds holding DXCM
Fjarde Ap-fonden's DXCM Position: Q2 2026 in Review
Fjarde Ap-fonden reduced its DexCom (DXCM) stake by 3.9% in Q2 2026, selling an estimated $440K and leaving 162,594 shares worth $11M. The position accounts for 0.05% of the portfolio, ranked #286.
Fjarde Ap-fonden first reported a position in DXCM in Q4 2016 and has held it in 34 quarters since. The position peaked at $14.6M in Q3 2021. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.
- Fjarde Ap-fonden held 162,594 shares of DexCom worth $11M as of Q2 2026.
- Fjarde Ap-fonden sold 6,600 DexCom shares in Q2 2026, an estimated $440K.
- DexCom made up 0.05% of Fjarde Ap-fonden's portfolio in Q2 2026, its #286 holding.
- Fjarde Ap-fonden first reported a position in DexCom in Q4 2016 and has held it in 34 quarters since.
- Fjarde Ap-fonden's DexCom position peaked at $14.6M in Q3 2021.
- 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.
Based on Fjarde Ap-fonden's 13F filing for Q2 2026, filed 29 Jul 2026.